Table 2.
Pre-Treatment Expectations and Post-Treatment Outcomes
| MET-E N = 388 |
MET-S N = 388 |
|||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| ‘Unsure’ | ‘Sure’ | F (df) | p | ‘Unsure’ | ‘Sure’ | F (df) | p | |
|
|
||||||||
| M (SD) | M (SD) | M (SD) | M (SD) | |||||
| % Drug Positive Urine in Treatment Period (28 days)* |
30.3 (40.7) |
30.1 (40.7) |
0 (1, 386) |
.958 | 49.4 (43.3) |
21.9 (35.7) |
18.83 (1, 153) |
<.001 |
| % Days Abstinent from Primary Drug in Treatment Period (Self-Report) |
91.6 (19.0) |
91.6 (20.2) |
0 (1, 369) |
.992 | 90.0 (19.0) |
96.3 (10.6) |
15.41 (1, 350) |
<.001 |
| % Days Abstinent from Primary Drug through Follow-Up Period (Self-Report) |
91.2 (15.8) |
92.3 (18.2) |
.29 (1, 314) |
.590 | 90.3 (19.8) |
96.3 (9.0) |
11.57 (1, 288) |
.001 |
| Treatment Retention (Days in Treatment through Follow-Up) |
67.8 (43.0) |
72.7 (42.3) |
1.2 (1, 381) |
.274 | 80.2 (38.7) |
84.0 (34.6) |
1.01 (1, 386) |
.303 |
*
This variable represents % urines positive for any drug in MET-E, but only for primary drug in MET-S